Humam Kadara
The University of Texas MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, RNA modifications and cancer, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities(2015)897 cited
- → Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial(2021)588 cited
- → Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance(2023)442 cited
- → Ursolic Acid Inhibits STAT3 Activation Pathway Leading to Suppression of Proliferation and Chemosensitization of Human Multiple Myeloma Cells(2007)234 cited
- → Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities(2020)225 cited
- → Comprehensive T cell repertoire characterization of non-small cell lung cancer(2020)222 cited
- → IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras–Mutant Lung Cancer(2016)215 cited
- → 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy(2021)211 cited
- → Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up(2016)209 cited
- → Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial(2023)193 cited